{
  "drugs": [
    {
      "drug": "Osimertinib",
      "proteins": [
        "EGFR"
      ],
      "mechanism": "Irreversible tyrosine kinase inhibitor binding to EGFR mutants (e.g., T790M), inhibits kinase activity and downstream signaling (PI3K/AKT, MAPK)",
      "fda_status": "FDA-approved (NSCLC; relevant to mesothelioma EGFR+)",
      "category": "mainstream"
    },
    {
      "drug": "Tipifarnib",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Farnesyltransferase inhibitor; blocks KRAS post-translational farnesylation required for membrane localization",
      "fda_status": "Investigational (Phase II in KRAS+ cancers)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Pembrolizumab",
      "proteins": [],
      "mechanism": "PD-1 checkpoint inhibitor; blocks immune checkpoint to enhance immune recognition and killing of cancer cells",
      "fda_status": "FDA-approved (first-line mesothelioma with chemotherapy)",
      "category": "mainstream"
    },
    {
      "drug": "Nivolumab",
      "proteins": [],
      "mechanism": "PD-1 checkpoint inhibitor; enhances immune-mediated tumor cell destruction",
      "fda_status": "FDA-approved (first-line mesothelioma with ipilimumab)",
      "category": "mainstream"
    },
    {
      "drug": "Ipilimumab",
      "proteins": [],
      "mechanism": "CTLA-4 checkpoint inhibitor; enhances T-cell activation and anti-tumor immunity",
      "fda_status": "FDA-approved (first-line mesothelioma with nivolumab)",
      "category": "mainstream"
    },
    {
      "drug": "Pemetrexed",
      "proteins": [],
      "mechanism": "Antifolate chemotherapy; inhibits thymidylate synthase and other folate-dependent enzymes",
      "fda_status": "FDA-approved (first-line mesothelioma with platinum agents)",
      "category": "mainstream"
    },
    {
      "drug": "Atorvastatin",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "HMG-CoA reductase inhibitor; blocks mevalonate pathway disrupting KRAS prenylation and membrane localization",
      "fda_status": "FDA-approved (hyperlipidemia, cardiovascular disease)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Simvastatin",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "HMG-CoA reductase inhibitor; blocks mevalonate pathway disrupting KRAS prenylation and membrane localization",
      "fda_status": "FDA-approved (hyperlipidemia, cardiovascular disease)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Efavirenz",
      "proteins": [
        "p53"
      ],
      "mechanism": "Non-nucleoside reverse transcriptase inhibitor; suppresses LINE-1 retrotransposition that stabilizes mutant p53",
      "fda_status": "FDA-approved (HIV infection)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Zoledronic acid",
      "proteins": [
        "KRAS"
      ],
      "mechanism": "Bisphosphonate; inhibits HMG-CoA reductase downstream effects, blocking KRAS farnesylation and membrane localization",
      "fda_status": "FDA-approved (osteoporosis, bone metastases)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Ibrutinib",
      "proteins": [
        "EGFR"
      ],
      "mechanism": "BTK inhibitor with off-target EGFR inhibition via reversible kinase domain binding",
      "fda_status": "FDA-approved (mantle cell lymphoma, chronic lymphocytic leukemia)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Adavosertib",
      "proteins": [
        "p53",
        "KRAS"
      ],
      "mechanism": "Wee1 kinase inhibitor; abrogates G2/M checkpoint, exploits p53 deficiency and sensitizes KRAS-mutant cells to DNA damage",
      "fda_status": "Investigational (advanced trials, ovarian cancer combinations)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Ganetespib",
      "proteins": [
        "p53"
      ],
      "mechanism": "HSP90 inhibitor; degrades mutant p53 via HSP90 client destabilization",
      "fda_status": "Investigational (Phase II solid tumors)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "UCN-01",
      "proteins": [
        "p53"
      ],
      "mechanism": "Protein kinase C inhibitor; Chk1 modulation restores p53-independent apoptosis in mutant lines",
      "fda_status": "Investigational (leukemia, lymphoma, SCLC trials)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "PEITC",
      "proteins": [
        "p53"
      ],
      "mechanism": "Phenethyl isothiocyanate; selectively inhibits p53 mutants (R175H/L), refolds/stabilizes mutant p53",
      "fda_status": "Not FDA-approved (nutraceutical/dietary supplement)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "APR-246",
      "proteins": [
        "p53"
      ],
      "mechanism": "p53 reactivator; reactivates p53 mutants (R273H/L), restores tumor suppression via DNA-binding domain correction",
      "fda_status": "Investigational (myelodysplastic syndrome, ovarian cancer trials)",
      "category": "repurposing_candidate"
    },
    {
      "drug": "Metformin",
      "proteins": [
        "EGFR",
        "KRAS"
      ],
      "mechanism": "AMPK activator; suppresses mTOR/EGFR-RAS signaling, inhibits metabolic reprogramming in KRAS-mutant cells",
      "fda_status": "FDA-approved (type 2 diabetes)",
      "category": "repurposing_candidate"
    }
  ],
  "cancer_type": "Pleural mesothelioma",
  "protein_targets": [
    "EGFR",
    "p53",
    "KRAS"
  ]
}